Effect of medication-related factors on adherence in people with schizophrenia: An European multi-centre study

Epidemiologia e Psichiatria Sociale

Volumn 19, Issue 3, 2010, Pages 251-259

  Meier, Johanna ^e   Becker, Thomas ^a   Patel, Anita ^b   Robson, Debbie ^b   Schene, Aart ^c   Kikkert, Martijn ^c   Barbui, Corrado ^d   Burti, Lorenzo ^d   Puschner, Bernd ^e  

^a UNIVERSITY OF ULM   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adherence; Antipsychotic drugs; Compliance; Multivariate analysis; Schizophrenia

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; EUROPE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; SCHIZOPHRENIA; STATISTICS;

ADULT; EUROPE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 78649294113     PISSN: 1121189X     EISSN: 20381816     Source Type: Journal    
DOI: 10.1705/524.6269     Document Type: Article

References (57)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual, 3rd Ed. Revised. American Psychiatric Press: Washington, DC.
2. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M. & Swanson J. (2006). Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6, 8-24.
3. Balestrieri M., Di Sciascio G., Isola M., Lomonaco E., Maso E., Merli R., Calo S. & Bellantuono C. (2009). Drug attitude and subjective well-being in antipsychotic treatment monotherapy in real-world settings. Epidemiologia e Psichiatria Sociale 18, 114-118.
4. Bordenave-Gabriel C., Giraud-Baro E., De Beauchamp I, Bougerol T. & Calop J. (2003). Why psychotic patients are not drug compliant? Encéphale 29, 213-222.
5. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magouirk B. & Rush A.J. (2005). A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 133, 129-133.
6. Chisholm D., Knapp M.R., Knudsen H.C., Amaddeo F., Gaite L. & van Wijngaarden B. (2000). Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. British Journal of Psychiatry, Suppl. 39, 28-33.
7. Claxton A. J., Cramer J. & Pierce C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 23, 1296-1310.
8. David A. (1990). Schedule for assessment of insight into psychosis. British Journal of Psychiatry 156, 798-803.
9. Davis J. M., Matalon L., Watanabe M.D., Blake L. & Metalon L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773.
10. Day J.C., Wood G., Dewey M. & Bentall R.P. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry 166, 650-653.
11. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P. & Power C. (2005). Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 62, 717-724.
12. Diaz E., Neuse E., Sullivan M.C., Pearsall H.R. & Woods S.W. (2004). Adherence to conventional and atypical antipsychotics after hospital discharge. Journal of Clinical Psychiatry 65, 354-360.
13. Dolder C.R., Lacro J.P., Dunn L.B. & Jeste D.V. (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 159, 103-108.
14. Donohoe G., Owens N., O'Donnell C., Burke T., Moore L., Tobin A. & O'Callaghan E. (2001). Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. European Psychiatry 16, 293-298.
15. Dunayevich E., Ascher-Svanum H., Zhao F., Jacobson J.G., Phillips G.A., Dellva M.A. & Green A.I. (2007). Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. Journal of Clinical Psychiatry 68, 1163-1171.
16. Fenton W.S., Blyler C.R. & Heinssen R.K. (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23, 637-651.
17. George C.F., Peveler R.C., Heiliger S. & Thompson C. (2000). Compliance with tricyclic antidepressants: the value of four different methods of assessment. British Journal of Clinical Pharmacology 50, 166-171.
18. Gianfrancesco F.D., Rajagopalan K., Sajatovic M. & Wang R.H. (2006). Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. Journal of Clinical Psychiatry 67, 222-232.
19. Gray R., Wykes T. & Gournay K. (2002). From compliance to concordance: A review of the literature on interventions to enhance compliance with antipsychotic medication. Journal of Psychiatric and Mental Health Nursing 9, 277-284.
20. Gray R., Leese M., Bindman J., Becker T., Burti L., David A., Gournay K., Kikkert M., Koeter M., Puschner B., Schene A., Thornicroft G. & Tansella M. (2006). Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. British Journal of Psychiatry 189, 508-514.
21. Grunebaum M.F., Weiden P.J. & Olfson M. (2001). Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. Journal of Clinical Psychiatry 62, 394-399.
22. Hogan T.P. & Awad A.G. (1992). Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychological Medicine 22, 347-352.
23. Hogan T.P., Awad A.G. & Eastwood R. (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 13, 177-183.
24. Hui C.L., Chen E.Y., Kan C., Yip K., Law C. & Chiu C.P. (2006). Antipsychotics adherence among out-patients with schizophrenia in Hong Kong. Keio Journal of Medicine 55, 9-14.
25. Jones S.H., Thornicroft G., Coffey M. & Dunn G. (1995). A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). British Journal of Psychiatry 166, 654-659.
26. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J. K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J. J., Hranov L. G., Gaebel W., Peuskens J., Lindefors N., Riecher-Roessler A. & Grobbee D. E. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097.
27. Kampman O., Laippala P., Vaananen J., Koivisto E., Kiviniemi P., Kilkku N. & Lehtinen K. (2002). Indicators of medication compliance in first-episode psychosis. Psychiatry Research 110, 39-48.
28. Kemp R. & David A. (1996). Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry 169, 444-450.
29. Kemp R., Kirov G., Everitt B., Hayward P. & David A. (1998). Randomised controlled trial of compliance therapy: 18-month follow- up. British Journal of Psychiatry 172, 413-419.
30. Kikkert M.J., Barbui C., Koeter M. W., David A.S., Leese M., Tansella M., Gieler A., Puschner B. & Schene A.H. (2008). Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. Journal of Nervous and Mental Disease 196, 274-281.
31. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G. & Jeste D.V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 63, 892-909.
32. Liao, T. F. (1994). Interpreting Probability Models. Sage: Thousand Oaks, California.
33. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J. & Hsiao J.K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
34. Llorca P.M., Miadi-Fargier H., Lancon C., Jasso M.G., Casadebaig F., Philippe A., Guillon P., Mehnert A., Omnes L.F., Chicoye A. & Durand-Zaleski I. (2005). Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encéphale 31, 235-246.
35. Loffler W., Kilian R., Toumi M. & Angermeyer M. C. (2003). Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 36, 105-112.
36. Menzin J., Boulanger L., Friedman M., Mackell J. & Lloyd J.R. (2003). Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatric Services 54, 719-723.
37. Morisky D.E., Green L.W. & Levine D.M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care 24, 67-74.
38. Morrison P., Gaskill D., Meehan T., Lunney P., Lawrence G. & Collings P. (2000). The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Australian and New Zealand Journal of Mental Health Nursing 9, 166-176.
39. Nageotte C., Sullivan G., Duan N. & Camp P.L. (1997). Medication compliance among the seriously mentally ill in a public mental health system. Social Psychiatry and Psychiatric Epidemiology 32, 49-56.
40. Nakonezny P.A. & Byerly M.J. (2006). Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophrenia Research 82, 107-114.
41. Nosé M., Barbui C., Gray R. & Tansella M. (2003). Clinical interventions for treatment non-adherence in psychosis: Meta-analysis. British Journal of Psychiatry 183, 197-206.
42. Novak-Grubic V. & Tavcar R. (1999). Treatment compliance in firstepisode schizophrenia. Psychiatric Services 50, 970-971.
43. Olfson M., Mechanic D., Hansell S., Boyer C.A., Walkup J. & Weiden P.J. (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 51, 216-222.
44. Razali M.S. & Yahya H. (1995). Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatrica Scandinavica 91, 331-335.
45. Rettenbacher M.A., Hofer A., Eder U., Hummer M., Kemmler G., Weiss E.M. & Fleischhacker W.W. (2004). Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Journal of Clinical Psychiatry 65, 1211-1218.
46. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D. & Lieberman J.A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56, 241-247.
47. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C. & Charney D. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine 337, 809-815.
48. Rosenheck R., Chang S., Choe Y., Cramer J., Xu W., Thomas J., Henderson W. & Charney D. (2000). Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry 61, 382-386.
49. Ruscher S.M., deWit R. & Mazmanian D. (1997). Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatric Services 48, 82-85.
50. Thieda P., Beard S., Richter A. & Kane J. (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services 54, 508-516.
51. Thornicroft G., Becker T., Knapp M., Schene A., Tansella M. & Vasquez Barquero J.L. (2000). Quality of Life Following Adherence Therapy for People Disabled by Schizophrenia and Their Carers (Study Protocol). Health Services Research Department at the Institute of Psychiatry: London.
52. Velligan D.I., Lam Y.W., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L. & Miller A.L. (2006). Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin 32, 724-742.
53. Ventura J., Green M.F., Shaner A. & Liberman R.P. (1993). Training and quality assurance with the brief psychiatric rating scale: 'The drift busters'. International Journal of Methods in Psychiatric Research 3, 221-244.
54. Viguera A.C., Baldessarini R.J., Hegarty J.D., van Kammen D.P. & Tohen M. (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry 54, 49-55.
55. Weiden P.J. & Olfson M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin 21, 419-429.
56. Wolters H.A., Knegtering H., van den Bosch R.J. & Wiersma D. (2009). Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophrenia Research 112, 114-118.
57. Young J.L., Zonana H.V. & Shepler L. (1986). Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law 14, 105-122.